Progressive decline of glucocerebrosidase in aging and Parkinson’s disease

Annals of Clinical and Translational Neurology

Volumn 2, Issue 4, 2015, Pages 433-438

  Rocha, Emily M ^a   Smith, Gaynor A ^a   Park, Eric ^b   Cao, Hongmei ^b   Brown, Eilish ^b   Hallett, Penelope ^a   Isacson, Ole ^a  

^a MCLEAN HOSPITAL   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84929870936     PISSN: None     EISSN: 23289503     Source Type: Journal    
DOI: 10.1002/ACN3.177     Document Type: Article

References (18)

1. Kasten M, Chade A, Tanner CM. Epidemiology of Parkinson’s disease. Handb Clin Neurol 2007;83:129-151.
2. Martinez-Vicente M, Sovak G, Cuervo AM. Protein degradation and aging. Exp Gerontol 2005;40:622-633.
3. Klionsky DJ. Autophagy: From phenomenology to molecular understanding in less than a decade. Nat Rev Mol Cell Biol 2007;8:931-937.
4. Chu CT, Zhu J, Dagda R. Beclin 1-independent pathway of damage-induced mitophagy and autophagic stress: Implications for neurodegeneration and cell death. Autophagy 2007;3:663-666.
5. Asselta R, Rimoldi V, Siri C, et al. Glucocerebrosidase mutations in primary parkinsonism. Parkinsonism Relat Disord 2014;20:1215-1220.
6. Lees AJ, Hardy J, Revesz T. Parkinson’s disease. Lancet 2009;373:2055-2066.
7. Neumann J, Bras J, Deas E, et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson’s disease. Brain. 2009;132(Pt 7):1783-1794.
8. Sidransky E, Lopez G. The link between the GBA gene and parkinsonism. Lancet Neurol 2012;11:986-998.
9. Clark LN, Ross BM, Wang Y, et al. Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease. Neurology 2007;69:1270-1277.
10. Bras J, Singleton A, Cookson MR, Hardy J. Emerging pathways in genetic Parkinson’s disease: Potential role of ceramide metabolism in Lewy body disease. FEBS J 2008;275:5767-5773.
11. Murphy KE, Gysbers AM, Abbott SK, et al. Reduced glucocerebrosidase is associated with increased alphasynuclein in sporadic Parkinson’s disease. Brain 2014. 137 (Pt 3):834-848.
12. Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson’s disease. N Engl J Med 2009;361:1651-1661.
13. Gegg ME, Burke D, Heales SJ, et al. Glucocerebrosidase deficiency in substantia nigra of Parkinson disease brains. Ann Neurol 2012;72:455-463.
14. Galvin JE, Lee VM, Trojanowski JQ. Synucleinopathies: Clinical and pathological implications. Arch Neurol 2001;58:186-190.
15. Bras J, Paisan-Ruiz C, Guerreiro R, et al. Complete screening for glucocerebrosidase mutations in Parkinson disease patients from Portugal. Neurobiol Aging 2009;30:1515-1517.
16. Brockmann K, Srulijes K, Pflederer S, et al. GBAassociated Parkinson’s disease: Reduced survival and more rapid progression in a prospective longitudinal study. Mov December 2014 [Epub ahead of print].
17. Mazzulli JR, Xu YH, Sun Y, et al. Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 2011;146:37-52.
18. Siebert M, Sidransky E, Westbroek W. Glucocerebrosidase is shaking up the synucleinopathies. Brain. 2014;137 (Pt 5):1304-1322.